


New combination therapy established as safe and effective for prostate cancer

25 June 2019



Marked reduction in metabolically active disease in response to a combination of ¹⁷⁷Lu PSMA 617 + NOX66 therapy in end-stage, high-volume castrate resistant metastatic prostate cancer. The PSA continued to fall for 6 months after completion of therapy, and the patient remains well 20 months after trial enrollment. Credit: Emmett L, Crumbaker M, Nguyen A, et al.

A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting.

Prostate cancer is the most commonly diagnosed cancer among men in the United States, other than [skin cancer](#). According to the American Cancer Society, approximately 175,000 new cases of prostate [cancer](#) are diagnosed and more than 31,500 men die from the disease annually in the United States.

Although there have been great treatment advances, metastatic castrate resistant [prostate cancer](#) (mCRPC) remains a deadly disease. Trials with the targeted radionuclide therapy ¹⁷⁷Lu PSMA 617 have proven safe and effective in some men; however, not all respond to treatment, and responses may be limited in duration. To build upon these trials, researchers paired ¹⁷⁷Lu PSMA 617 with the tumor-specific radiation sensitizer

idronoxil (NOX66) to assess responses in patients with heavily treated mCRPC.

The phase I/II trial enrolled 16 men with progressing mCRPC, despite previous treatments. All men received up to six doses of ¹⁷⁷Lu PSMA 617 at six-week intervals. Half the patients (cohort 1) received additional treatment of 400mg NOX66 daily for ten days. Following a safety data review, the remaining patients (cohort 2) received additional treatment of 800mg NOX66 daily.

Researchers found that nearly 70 percent of all patients saw a more than 50 percent reduction in their PSA levels (62.5 percent in cohort 1 and 75 percent in cohort 2) after the combination treatment. Furthermore, adverse [side effects](#), such as fatigue and pneumonitis, were reported in 31 percent of all patients (37.5 percent in cohort 1 and 12.5 percent in cohort 2).

"The initial results of this phase I dose escalation study show that the combination targeted treatments were well tolerated together, with no increase in toxicity from ¹⁷⁷Lu PSMA 617, and an apparent high efficacy in men who have already had extensive treatments," said Louise Emmett, MD, associate professor at the University of New South Wales in Sydney, Australia.

She continued, "We are now in a dose expansion phase II stage to further evaluate toxicity and efficacy. This raises the very important possibilities of combining tumor-targeted therapeutic agents to gain synergistic treatment effects without an increase in side effects."

More information: Abstract 465. "Interim Results of a Phase I/II Prospective Dose Escalation Trial Evaluating Safety and Efficacy of Combination ¹⁷⁷Lu PSMA 617 and NOX66 in Men with mCRPC Post Androgen Signalling Inhibition and 2 Lines of Taxane Chemotherapy (LuPIN Trial)."

Provided by Society of Nuclear Medicine and
Molecular Imaging

APA citation: New combination therapy established as safe and effective for prostate cancer (2019, June 25) retrieved 22 October 2021 from <https://medicalxpress.com/news/2019-06-combination-therapy-safe-effective-prostate.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.